Relay Therapeutics, Inc.
RLAY
$3.26
$0.061.88%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 0.00 | -- | -- | 10.01M | -1.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 0.00 | -- | -- | 10.01M | -1.00K |
| Cost of Revenue | 64.43M | 76.62M | 91.99M | 82.40M | 73.87M |
| Gross Profit | -64.43M | -76.62M | -91.99M | -72.40M | -73.87M |
| SG&A Expenses | 20.55M | 19.75M | 20.14M | 19.80M | 20.40M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 84.98M | 96.37M | 112.13M | 102.20M | 94.26M |
| Operating Income | -84.98M | -96.37M | -112.13M | -92.20M | -94.26M |
| Income Before Tax | -76.00M | -88.11M | -92.21M | -81.39M | -83.50M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -76.00M | -88.11M | -92.21M | -81.39M | -83.50M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -76.00M | -88.11M | -92.21M | -81.39M | -83.50M |
| EBIT | -84.98M | -96.37M | -112.13M | -92.20M | -94.26M |
| EBITDA | -83.65M | -95.00M | -110.76M | -90.80M | -92.89M |
| EPS Basic | -0.45 | -0.63 | -0.69 | -0.62 | -0.67 |
| Normalized Basic EPS | -0.28 | -0.39 | -0.49 | -0.40 | -0.43 |
| EPS Diluted | -0.45 | -0.63 | -0.69 | -0.62 | -0.67 |
| Normalized Diluted EPS | -0.28 | -0.39 | -0.49 | -0.40 | -0.43 |
| Average Basic Shares Outstanding | 167.34M | 140.23M | 132.82M | 130.84M | 124.75M |
| Average Diluted Shares Outstanding | 167.34M | 140.23M | 132.82M | 130.84M | 124.75M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |